Search Results
MS highlights at AAN: BTK inhibitors
BTK Inhibition and the Future of MS Management
Review of BTK inhibition in MS
The Road Ahead for BTK Inhibitors in Multiple Sclerosis
BTK inhibitors gain ground in MS
Fernando Dangond, AAN 2019 – Phase II study of first oral BTK inhibitor in multiple sclerosis
Masitinib: What we've been waiting for?
Therapeutic strategies targeting smoldering neuroinflammation in MS
BTK inhibitors for multiple sclerosis: progressive disease and de-escalation
Long-term safety and efficacy of tolebrutinib for relapsing multiple sclerosis
Stephen L. Hauser, MD: Fenebrutinib and BTK Inhibiton in Progressive MS
Xavier Montalban, EAN 2019 – Phase II study of first oral BTK inhibitor in multiple sclerosis